SS
BIOTU

Steve Schonfeld’s Biotech Acquisition Company Unit BIOTU Stock Holding History

Steve Schonfeld’s Portfolio BIOTU Stock Details BIOTU Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-44,498
Closed -$447K – 2721
2021
Q3 		$447K Hold
44,498
– – ﹤0.01% 1327
2021
Q2 		$449K Sell
44,498
-50,002
-53% -$501K ﹤0.01% 1251
2021
Q1 		$935K Buy
+94,500
New +$972K 0.01% 924

Other funds holding BIOTU

HF
HRT Financial New York $54.8B AUM 81.03% 1-Year Est. Return
SMA
Sage Mountain Advisors Atlanta, Georgia $1.63B AUM 18.97% 1-Year Est. Return
COPPSERS
Commonwealth of Pennsylvania Public School Employees Retirement System Harrisburg, Pennsylvania $20.6B AUM 37.37% 1-Year Est. Return
WCMNY
Westchester Capital Management (New York) Valhalla, New York $2.04B AUM 31.03% 1-Year Est. Return
WC
Wealthspring Capital West Harrison, New York $448M AUM 8.38% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
SIA
Schechter Investment Advisors Birmingham, Michigan $1.21B AUM 8.73% 1-Year Est. Return
BCM
BCK Capital Management Stamford, Connecticut $23M AUM 33.03% 1-Year Est. Return
Walleye Capital
Walleye Capital New York $28B AUM 44.22% 1-Year Est. Return

Steve Schonfeld's BIOTU Position: Q4 2021 in Review

Steve Schonfeld sold out of Biotech Acquisition Company Unit (BIOTU) in Q4 2021, closing a stake of 44,498 shares — an estimated $447K sold.

Steve Schonfeld first reported a position in BIOTU in Q1 2021 and held it in 3 quarters. The position peaked at $935K in Q1 2021. 15 funds tracked by Wall St. Rank hold BIOTU as of Q4 2021.

  • Steve Schonfeld reported no remaining Biotech Acquisition Company Unit position as of Q4 2021 after selling out during the quarter.
  • Steve Schonfeld sold 44,498 Biotech Acquisition Company Unit shares in Q4 2021, an estimated $447K.
  • Steve Schonfeld first reported a position in Biotech Acquisition Company Unit in Q1 2021 and held it in 3 quarters.
  • Steve Schonfeld's Biotech Acquisition Company Unit position peaked at $935K in Q1 2021.
  • 15 funds tracked by Wall St. Rank held Biotech Acquisition Company Unit as of Q4 2021.

Based on Schonfeld Strategic Advisors's 13F filing for Q4 2021, filed 14 Feb 2022.